Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
SGYP's Cash to Debt is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. SGYP: No Debt )
SGYP' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: 4.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -119.24
SGYP's ROE (%) is ranked lower than
54% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. SGYP: -119.24 )
SGYP' s 10-Year ROE (%) Range
Min: -899.32   Max: -154.96
Current: -119.24

-899.32
-154.96
ROA (%) -96.96
SGYP's ROA (%) is ranked lower than
56% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.06 vs. SGYP: -96.96 )
SGYP' s 10-Year ROA (%) Range
Min: -6858.53   Max: -112.99
Current: -96.96

-6858.53
-112.99
ROC (Joel Greenblatt) (%) -13238.08
SGYP's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.08 vs. SGYP: -13238.08 )
SGYP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -423053.33   Max: -20132.79
Current: -13238.08

-423053.33
-20132.79
EBITDA Growth (%) 29.00
SGYP's EBITDA Growth (%) is ranked higher than
90% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. SGYP: 29.00 )
SGYP' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 122.4
Current: 29

0
122.4
EPS Growth (%) 29.00
SGYP's EPS Growth (%) is ranked higher than
88% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. SGYP: 29.00 )
SGYP' s 10-Year EPS Growth (%) Range
Min: 0   Max: 122.4
Current: 29

0
122.4
» SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SGYP Guru Trades in

Q4 2013

SGYP Guru Trades in Q4 2013

Jim Simons 208,600 sh (New)
» More
Q1 2014

SGYP Guru Trades in Q1 2014

Jim Simons 197,390 sh (-5.37%)
» More
Q2 2014

SGYP Guru Trades in Q2 2014

Paul Singer 450,400 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.15
SGYP's P/B is ranked higher than
54% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. SGYP: 7.15 )
SGYP' s 10-Year P/B Range
Min: 0   Max: 46.2
Current: 7.15

0
46.2
EV-to-EBIT -3.28
SGYP's EV-to-EBIT is ranked lower than
52% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. SGYP: -3.28 )
SGYP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.28

Current Ratio 3.12
SGYP's Current Ratio is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SGYP: 3.12 )
SGYP' s 10-Year Current Ratio Range
Min: 0.04   Max: 11.88
Current: 3.12

0.04
11.88
Quick Ratio 3.12
SGYP's Quick Ratio is ranked higher than
83% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. SGYP: 3.12 )
SGYP' s 10-Year Quick Ratio Range
Min: 0.04   Max: 11.88
Current: 3.12

0.04
11.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.37
SGYP's Price/Net Cash is ranked higher than
93% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SGYP: 8.37 )
SGYP' s 10-Year Price/Net Cash Range
Min: 4.63   Max: 581.6
Current: 8.37

4.63
581.6
Price/Net Current Asset Value 8.37
SGYP's Price/Net Current Asset Value is ranked higher than
90% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SGYP: 8.37 )
SGYP' s 10-Year Price/Net Current Asset Value Range
Min: 4.63   Max: 301.65
Current: 8.37

4.63
301.65
Price/Tangible Book 7.15
SGYP's Price/Tangible Book is ranked higher than
63% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.72 vs. SGYP: 7.15 )
SGYP' s 10-Year Price/Tangible Book Range
Min: 4.44   Max: 517.9
Current: 7.15

4.44
517.9
Forward Rate of Return (Yacktman) 23.69
SGYP's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SGYP: 23.69 )
SGYP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: 23.69

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S90.Germany
Synergy Pharmaceuticals, Inc. was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. On July 14, 2008 it acquired 100% of the common stock of Synergy Pharmaceuticals, Inc. a Delaware company. On July 21, 2008, it amended its articles of incorporation to effect the actions necessary to complete the transactions contemplated by the Exchange Transaction and changed its name from Pawfect Foods, Inc. to Synergy Pharmaceuticals, Inc. It is now exclusively a development stage biopharmaceutical company, whose main focus is on the development of drugs to treat GI disorders and diseases. The Company's drug candidates, acquired from Synergy-DE in connection with the Exchange Transaction, are as follows: SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, mainly chronic constipation ('CC') and constipation-predominant irritable bowel syndrome (IBS-C); and SP-333, a second generation GC-C receptor analog, in pre-clinical development for the treatment of ulcerative colitis (UC). SP-304 is a new member of a novel class of non-systemic drugs for treatment of chronic constipation (CC), irritable bowel syndrome with constipation (IBS-C) and other GI disorders and diseases. SP-304 was developed by Synergy scientists based on structure-function studies performed in-house. SP-304 has been demonstrated to be superior to uroguanylin in its biological activity, protease stability and pH characteristics. SP-304 acts in an identical manner as the natural hormone- as an agonist (i.e. activator) of the GC-C receptor found on the epithelial cells of the colon. Upon activation, the GC-C receptor promotes intracellular synthesis which in turn eventually activates the cystic fibrosis transmembrane conductance regulator (CFTR) within the epithelial cells. Activation of CFTR leads to secretion of salts and water into the intestine, resulting in a liquid and watery intestine content that is more easily transported through the bowel. Recent animal studies performed with SP-304 have demonstrated the drugs potential to enhance intestinal motility. SP-304 previously was evaluated in animal studies as a treatment for GI inflammation in a collaborative study involving clinical gastroenterologist Dr. Scott Plevy of the University of North Carolina, Chapel Hill, NC. Results from his laboratory showed that SP-304 was efficacious in animal models of UC. A second generation GC-C receptor agonist SP-333 with improved stability properties is now in pre-clinical development and Synergy plans to file an IND on SP-333 to treat UC patients, and initiate a Phase I clinical trial in volunteers in fourth quarter of 2010. The biopharmaceutical industry is characterized by rapidly evolving technology and intense competition. The Company's competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood (Microbia), Sucampo/Takeda and Novartis. Regulation by governmental authorities
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 19 2014
Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in... Sep 18 2014
ContraVir to Present at Two Upcoming Investor Conferences Sep 03 2014
SYNERGY PHARMACEUTICALS, INC. Financials Aug 19 2014
Synergy Pharma (SGYP) Posts Wider-than-Expected Loss in Q2 Aug 13 2014
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
SYNERGY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
Synergy Pharmaceuticals Reports Second Quarter and First Half 2014 Financial Results Aug 11 2014
Synergy Pharmaceuticals to Present at Canaccord Genuity Growth Conference Aug 06 2014
Synergy Pharmaceuticals Progresses with Mid-Stage Candidate Jul 18 2014
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 17 2014
Weakness Seen in Lannett Company (LCI): Stock Tumbles 17.1% Jul 17 2014
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% Jul 17 2014
Synergy Pharmaceuticals Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with... Jul 17 2014
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 15 2014
Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% Jul 14 2014
Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in... Jul 14 2014
Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4% Jul 10 2014
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% Jul 10 2014
Synergy Pharmaceuticals' Plecanatide to Move into Phase III Jul 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK